Effects of Rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome
Journal
American Journal of Cardiology
Journal Volume
93
Journal Issue
3
Pages
362
Date Issued
2004-02-01
Author(s)
Abstract
Fifty nondiabetic patients who met a modified National Cholesterol Education Program definition for the metabolic syndrome were randomized to receive either rosiglitazone (4 mg/day; n = 25) or placebo (n = 25) for 8 weeks. Compared with those receiving placebo, patients in the rosiglitazone group achieved significant reductions in fasting plasma insulin levels (-40%), homeostasis model assessment indexes (-45%), systolic and diastolic blood pressures, and high-sensitivity C-reactive protein levels (-31%). There were no changes in fasting plasma glucose with either treatment. Although rosiglitazone treatment greatly increased plasma levels of low-density lipoprotein cholesterol (18%) and apolipoprotein B (16%), it significantly improved both endothelium-dependent flow-mediated vasodilation (p <0.001) and endothelium-independent nitroglycerin-induced vasodilation (p = 0.01) of the right brachial artery. ? 2004 by Excerpta Medica, Inc.
SDGs
Other Subjects
2,4 thiazolidinedione derivative; antidiabetic agent; apolipoprotein B; C reactive protein; glucose; glyceryl trinitrate; insulin; low density lipoprotein cholesterol; placebo; rosiglitazone; adult; aged; artery endothelium; article; brachial artery; clinical article; clinical trial; controlled clinical trial; controlled study; coronary artery blood flow; diastolic blood pressure; double blind procedure; drug effect; female; glucose blood level; glucose homeostasis; health program; human; insulin blood level; intermethod comparison; male; medical assessment; metabolic syndrome X; metabolism; priority journal; protein blood level; randomization; randomized controlled trial; sample size; systolic blood pressure; vasodilatation
Type
journal article